| 1 | Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation | 2.2 | 1 | Citations (PDF) |
| 2 | Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial | 3.8 | 1 | Citations (PDF) |
| 3 | High-dimensional droplet digital PCR of multiple hepatitis B splice variants in serum, liver, and tissue culture | 1.0 | 1 | Citations (PDF) |
| 4 | Health economic outcomes of a minimal monitoring approach to providing HCV therapy | 3.3 | 0 | Citations (PDF) |
| 5 | Metformin and Time to Sustained Recovery in Adults With COVID-19 | 8.3 | 7 | Citations (PDF) |
| 6 | Hepatitis C Treatment in People With HIV: Potential to Eliminate Disease and Disparity | 2.2 | 6 | Citations (PDF) |
| 7 | Outcomes of early vs late treatment initiation in solid organ transplantation from hepatitis C virus nucleic acid test-positive donors to hepatitis C virus-uninfected recipients: Results from the HCV-TARGET study | 3.6 | 14 | Citations (PDF) |
| 8 | Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States | 2.6 | 60 | Citations (PDF) |
| 9 | Changes in Inflammatory Cytokines After Chronic Hepatitis C Treatment Among People Living With HIV | 0.7 | 3 | Citations (PDF) |
| 10 | Long-term open-label vebicorvir for chronic HBV infection: Safety and off-treatment responses | 3.5 | 4 | Citations (PDF) |
| 11 | Diagnostic Ability of Simple Noninvasive Blood Tests to Predict Increased Liver Stiffness in People Living With HIV and Steatotic Liver Disease | 0.6 | 9 | Citations (PDF) |
| 12 | Loneliness and fearfulness are associated with non-fatal drug overdose among people who inject drugs | 1.5 | 5 | Citations (PDF) |
| 13 | Hepatitis C and Cigarette Smoking Behavior: Themes From Focus Groups | 1.4 | 6 | Citations (PDF) |
| 14 | Leveraging opportunities for treatment/user simplicity (LOTUS): Navigating the current treatment landscape for achieving hepatitis C virus elimination among persons who inject drugs | 1.2 | 1 | Citations (PDF) |
| 15 | Title is missing! 2024 | | 0 | Citations (PDF) |
| 16 | Time to Sustained Recovery Among Outpatients With COVID-19 Receiving Montelukast vs Placebo | 5.2 | 6 | Citations (PDF) |
| 17 | A Prospective Cohort Study of Novel Markers of Hepatitis B Virus Replication in Human Immunodeficiency Virus Coinfection | 5.3 | 7 | Citations (PDF) |
| 18 | A prospective cohort study of renal function and bone turnover in adults with hepatitis B virus (HBV)‐HIV co‐infection with high prevalence of tenofovir‐based antiretroviral therapy use | 1.8 | 4 | Citations (PDF) |
| 19 | HBV transcription and translation persist despite viral suppression in HBV‐HIV co‐infected patients on antiretroviral therapy | 9.5 | 13 | Citations (PDF) |
| 20 | Liver Inflammation Is Common and Linked to Metabolic Derangements in Persons With Treated Human Immunodeficiency Virus (HIV) | 3.8 | 13 | Citations (PDF) |
| 21 | It Is Time for a Simplified Approach to Hepatitis B Elimination | 1.2 | 25 | Citations (PDF) |
| 22 | Evaluation of a pilot emergency department linkage to care program for patients previously diagnosed with Hepatitis C | 1.2 | 5 | Citations (PDF) |
| 23 | Effect of Fluvoxamine vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19 | 15.8 | 65 | Citations (PDF) |
| 24 | Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment | 3.8 | 9 | Citations (PDF) |
| 25 | Chronic Hepatitis C | 1.9 | 12 | Citations (PDF) |
| 26 | Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus | 2.2 | 4 | Citations (PDF) |
| 27 | Effect of Higher-Dose Ivermectin for 6 Days vs Placebo on Time to Sustained Recovery in Outpatients With COVID-19 | 15.8 | 76 | Citations (PDF) |
| 28 | Hepatitis D virus infection: Progress on the path toward disease control and cure | 1.2 | 2 | Citations (PDF) |
| 29 | Lessons From COVID-19 for Pandemic Preparedness: Proceedings From a Multistakeholder Think Tank | 3.8 | 22 | Citations (PDF) |
| 30 | Inhaled Fluticasone Furoate for Outpatient Treatment of Covid-19 | 19.4 | 26 | Citations (PDF) |
| 31 | Hepatitis C in Black Individuals in the US | 15.8 | 12 | Citations (PDF) |
| 32 | Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus | 5.3 | 63 | Citations (PDF) |
| 33 | Evolution of Fatty Liver Disease and Relationship With Lipoproteins and Clinical Outcomes in Hepatitis B/Human Immunodeficiency Virus Coinfection | 3.8 | 1 | Citations (PDF) |
| 34 | Nonadherence to Ledipasvir/Sofosbuvir Did Not Predict Sustained Virologic Response in a Randomized Controlled Trial of Human Immunodeficiency Virus/Hepatitis C Virus Coinfected Persons Who Use Drugs | 2.2 | 7 | Citations (PDF) |
| 35 | Preferences of Persons With or at Risk for Hepatitis C for Long-Acting Treatments | 3.8 | 9 | Citations (PDF) |
| 36 | Validation of a tool to assess effectiveness of peer-recruitment for hepatitis C testing and linkage to care among people who inject drugs | 0.8 | 1 | Citations (PDF) |
| 37 | Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis | 9.5 | 41 | Citations (PDF) |
| 38 | A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial | 14.9 | 103 | Citations (PDF) |
| 39 | A simplified algorithm for managing hepatitis C infection by leveraging telemedicine | 0.0 | 1 | Citations (PDF) |
| 40 | Clostridioides difficile infection (CDI) in a previous room occupant predicts CDI in subsequent room occupants across different hospital settings | 1.5 | 9 | Citations (PDF) |
| 41 | Long-term Follow-up of Hepatitis C Patients Who Achieved Sustained Virologic Response in the Pragmatic PRIORITIZE Study | 5.3 | 1 | Citations (PDF) |
| 42 | Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment | 2.6 | 15 | Citations (PDF) |
| 43 | Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection | 7.4 | 35 | Citations (PDF) |
| 44 | Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection | 7.4 | 42 | Citations (PDF) |
| 45 | Integrated hepatitis B virus DNA maintains surface antigen production during antiviral treatment | 6.8 | 78 | Citations (PDF) |
| 46 | The health economic outcomes of trial ACTG5360/MINMON | 7.4 | 1 | Citations (PDF) |
| 47 | Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection | 2.7 | 12 | Citations (PDF) |
| 48 | Fatty Liver Disease in a Prospective North American Cohort of Adults With Human Immunodeficiency Virus and Hepatitis B Virus Coinfection | 3.8 | 20 | Citations (PDF) |
| 49 | Retrospective-prospective study of safety and efficacy of sofosbuvir-based direct-acting antivirals in HIV/HCV-coinfected participants with decompensated liver disease pre– or post–liver transplant | 3.6 | 19 | Citations (PDF) |
| 50 | Four-Week Direct-Acting Antiviral Prophylaxis for Kidney Transplantation From Hepatitis C–Viremic Donors to Hepatitis C–Negative Recipients: An Open-Label Nonrandomized Study | 7.3 | 46 | Citations (PDF) |
| 51 | T-cell Activation Is Correlated With Monocyte Activation in HCV/HIV Coinfection and Declines During HCV Direct-Acting Antiviral Therapy | 0.7 | 9 | Citations (PDF) |
| 52 | Perceptions of network based recruitment for hepatitis C testing and treatment among persons who inject drugs: a qualitative exploration | 2.2 | 19 | Citations (PDF) |
| 53 | Hepatitis B Virus/Hepatitis D Virus–Coinfected Liver Transplant Candidate Receiving Hepatitis B Virus-Deoxyribonucleic Acid–Positive Allograft and Treated With High-Dose Hepatitis B Immune Globulin | 0.4 | 4 | Citations (PDF) |
| 54 | A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study | 9.5 | 13 | Citations (PDF) |
| 55 | A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV‐HIV Co‐infected Adults in North America | 9.5 | 20 | Citations (PDF) |
| 56 | Impact of co-occurring drug use, hazardous alcohol use and mental health disorders on drug use patterns in people living with HIV and hepatitis C virus infection | 0.7 | 1 | Citations (PDF) |
| 57 | Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017–2019 | 2.7 | 11 | Citations (PDF) |
| 58 | HCV communication within ego-centric networks of men and women who inject drugs | 0.8 | 6 | Citations (PDF) |
| 59 | Evaluating Noninvasive Markers to Identify Advanced Fibrosis by Liver Biopsy in HBV/HIV Co‐infected Adults | 9.5 | 40 | Citations (PDF) |
| 60 | Patient’s Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site | 0.8 | 14 | Citations (PDF) |
| 61 | Unreported alcohol use was common but did not impact hepatitis C cure in HIV‐infected persons who use drugs | 1.2 | 9 | Citations (PDF) |
| 62 | Single Hepatocyte Hepatitis B Virus Transcriptional Landscape in HIV Coinfection | 2.2 | 33 | Citations (PDF) |
| 63 | Nurse case management to improve the hepatitis C care continuum in HIV co‐infection: Results of a randomized controlled trial | 1.2 | 16 | Citations (PDF) |
| 64 | Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland | 1.2 | 11 | Citations (PDF) |
| 65 | Replacing Insulin with Anti-Virals: A Clinical Vignette on Diabetes and HCV Treatment | 0.4 | 2 | Citations (PDF) |
| 66 | Factors associated with phylogenetic clustering of hepatitis C among people who inject drugs in Baltimore | 1.7 | 12 | Citations (PDF) |
| 67 | Hepatitis C treatment uptake among people who inject drugs in the oral direct‐acting antiviral era | 3.1 | 48 | Citations (PDF) |
| 68 | Timing of hepatitis C elimination in the United States: estimating the year each state will meet the World Health Organization’s elimination targets | 7.4 | 0 | Citations (PDF) |
| 69 | Déjà vu All Over Again: Retreatment of HCV Direct Acting Antivirals Failures—Same Satisfactory Results, Same Unanswered Questions | 3.8 | 0 | Citations (PDF) |
| 70 | Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult | 2.2 | 13 | Citations (PDF) |
| 71 | Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non‐adherence | 2.6 | 25 | Citations (PDF) |
| 72 | Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine | 5.3 | 26 | Citations (PDF) |
| 73 | Sa1527 DEVELOPMENT OF A LONG-ACTING DIRECT-ACTING ANTIVIRAL SYSTEM FOR HEPATITIS C VIRUS TREATMENT IN A SWINE MODEL | 0.9 | 3 | Citations (PDF) |
| 74 | Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus–HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation | 2.2 | 12 | Citations (PDF) |
| 75 | Individual and network factors associated with HCV treatment uptake among people who inject drugs | 2.2 | 28 | Citations (PDF) |
| 76 | Management of the Patient With HIV/Hepatitis C Drug Interactions: A Guide for Nurses and Nurse Practitioners | 0.6 | 0 | Citations (PDF) |
| 77 | Network‐based recruitment of people who inject drugs for hepatitis C testing and linkage to care | 1.2 | 24 | Citations (PDF) |
| 78 | Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy | 2.2 | 8 | Citations (PDF) |
| 79 | Estimating the Year Each State in the United States Will Achieve the World Health Organization’s Elimination Targets for Hepatitis C | 2.7 | 33 | Citations (PDF) |
| 80 | Ethical and Practical Issues Associated With the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine | 3.8 | 9 | Citations (PDF) |
| 81 | Single hepatocytes show persistence and transcriptional inactivity of hepatitis B | 3.7 | 32 | Citations (PDF) |
| 82 | Public Masking: An Urgent Need to Revise Global Policies to Protect against COVID-19 | 0.6 | 12 | Citations (PDF) |
| 83 | The Proof Is in the Patient: Hepatitis C Virus Microelimination in the Swiss Human Immunodeficiency Virus Cohort Study | 3.8 | 4 | Citations (PDF) |
| 84 | Hepatitis C‐positive donor liver transplantation for hepatitis C seronegative recipients | 1.2 | 45 | Citations (PDF) |
| 85 | Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy | 0.9 | 38 | Citations (PDF) |
| 86 | Hepatitis C Elimination in People With HIV Is Contingent on Closing Gaps in the HIV Continuum | 0.7 | 22 | Citations (PDF) |
| 87 | Correlation Between Tenofovir Drug Levels and the Renal Biomarkers RBP-4 and ß2M in the ION-4 Study Cohort | 0.7 | 12 | Citations (PDF) |
| 88 | Advanced liver fibrosis and care continuum in emergency department patients with chronic hepatitis C | 1.2 | 3 | Citations (PDF) |
| 89 | Barriers and facilitators of hepatitis C treatment uptake among people who inject drugs enrolled in opioid treatment programs in Baltimore | 2.4 | 62 | Citations (PDF) |
| 90 | A Randomized Controlled Trial of Cash Incentives or Peer Support to Increase HCV Treatment for Persons With HIV Who Use Drugs: The CHAMPS Study | 0.7 | 46 | Citations (PDF) |
| 91 | Overlapping epidemics of alcohol and illicit drug use among HCV-infected persons who inject drugs | 2.1 | 16 | Citations (PDF) |
| 92 | Center-level trends in utilization of HCV-exposed donors for HCV-uninfected kidney and liver transplant recipients in the United States | 3.6 | 46 | Citations (PDF) |
| 93 | 2549. Variance Between Clinicians and Guidelines in Management of HIV/HCV Coinfection | 0.7 | 0 | Citations (PDF) |
| 94 | Spectrum of Liver Disease in Hepatitis B Virus (HBV) Patients Co-infected with Human Immunodeficiency Virus (HIV): Results of the HBV-HIV Cohort Study | 0.6 | 38 | Citations (PDF) |
| 95 | Cigarette Smoking in Persons Living with Hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999-2014 | 1.6 | 34 | Citations (PDF) |
| 96 | Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection | 1.2 | 10 | Citations (PDF) |
| 97 | Understanding and addressing hepatitis C reinfection in the oral direct‐acting antiviral era | 1.2 | 99 | Citations (PDF) |
| 98 | Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India | 2.2 | 10 | Citations (PDF) |
| 99 | Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study | 3.8 | 144 | Citations (PDF) |
| 100 | Directly observed therapy of sofosbuvir/ribavirin +/− peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C‐DOT) | 1.2 | 7 | Citations (PDF) |
| 101 | Utilization of hepatitis C virus RNA–positive donor liver for transplant to hepatitis C virus RNA–negative recipient | 1.6 | 36 | Citations (PDF) |
| 102 | Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir‐containing regimens | 1.2 | 3 | Citations (PDF) |
| 103 | A164 RAPID INTRAHEPATIC AND PERIPHERAL BLOOD HCV RNA DECLINE AND HCV-SPECIFIC IMMUNE RESPONSE INCREASE DURING IFN-FREE DAA THERAPY IN HCV TREATMENT-NAÏVE PATIENTS | 0.3 | 1 | Citations (PDF) |
| 104 | Care2Cure: A randomized controlled trial protocol for evaluating nurse case management to improve the hepatitis C care continuum within HIV primary care | 1.3 | 5 | Citations (PDF) |
| 105 | The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States | 7.3 | 193 | Citations (PDF) |
| 106 | An Education and Field Experience Program to Increase Detection of Human Immunodeficiency Virus and Hepatitis C Virus | 0.4 | 4 | Citations (PDF) |
| 107 | Direct-Acting Antiviral Prophylaxis in Kidney Transplantation From Hepatitis C Virus–Infected Donors to Noninfected Recipients | 7.3 | 295 | Citations (PDF) |
| 108 | Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey | 1.2 | 15 | Citations (PDF) |
| 109 | Association of CYP2B6 Single-Nucleotide Polymorphisms Altering Efavirenz Metabolism With Hepatitis C Virus (HCV) Treatment Relapse Among Human Immunodeficiency Virus/HCV–Coinfected African Americans Receiving Ledipasvir/Sofosbuvir in the ION-4 Trial | 3.8 | 0 | Citations (PDF) |
| 110 | Changes in Utilization and Discard of HCV Antibody-Positive Deceased Donor Kidneys in the Era of Direct-Acting Antiviral Therapy | 1.7 | 39 | Citations (PDF) |
| 111 | Cigarette Smoking Behaviors and Beliefs in Persons Living With Hepatitis C | 1.4 | 12 | Citations (PDF) |
| 112 | NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome | 7.4 | 211 | Citations (PDF) |
| 113 | Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment | 9.5 | 185 | Citations (PDF) |
| 114 | Challenges in treatment of hepatitis C among patients with hepatocellular carcinoma | 9.5 | 19 | Citations (PDF) |
| 115 | Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study | 3.2 | 2 | Citations (PDF) |
| 116 | Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis | 7.4 | 285 | Citations (PDF) |
| 117 | Patient‐reported outcomes in patients co‐infected with hepatitis C virus and human immunodeficiency virus treated with sofosbuvir and velpatasvir: The ASTRAL‐5 study | 3.1 | 32 | Citations (PDF) |
| 118 | Sofosbuvir‐velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct‐acting antiviral regimen | 9.5 | 82 | Citations (PDF) |
| 119 | Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study | 9.5 | 155 | Citations (PDF) |
| 120 | Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study | 10.4 | 77 | Citations (PDF) |
| 121 | Changes in Utilization and Discard of Hepatitis C–Infected Donor Livers in the Recent Era | 3.6 | 101 | Citations (PDF) |
| 122 | Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease | 3.8 | 11 | Citations (PDF) |
| 123 | Sofosbuvir and Velpatasvir for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus Type 1: An Open-Label, Phase 3 Study | 3.8 | 158 | Citations (PDF) |
| 124 | Increased Mortality Among Persons With Chronic Hepatitis C With Moderate or Severe Liver Disease: A Cohort Study | 3.8 | 17 | Citations (PDF) |
| 125 | Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection | 7.3 | 655 | Citations (PDF) |
| 126 | Short‐duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study) | 3.1 | 32 | Citations (PDF) |
| 127 | Time to viral suppression is not related to achievement of SVR12 in HCV GT1‐infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin | 1.2 | 8 | Citations (PDF) |
| 128 | I-105 Advances in the treatment of chronic HCV infection with direct acting antivirals | 1.1 | 0 | Citations (PDF) |
| 129 | Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies | 3.8 | 103 | Citations (PDF) |
| 130 | Hepatitis C Virus Postexposure Prophylaxis in the Healthcare Worker: Why Direct-Acting Antivirals Don't Change a Thing | 3.8 | 22 | Citations (PDF) |
| 131 | Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era | 0.7 | 23 | Citations (PDF) |
| 132 | Reply to Ozaras et al | 3.8 | 4 | Citations (PDF) |
| 133 | Building a Community - Academic Partnership to Enhance Hepatitis C Virus Screening 2016, 6, | | 7 | Citations (PDF) |
| 134 | Primary Care Providers Knowledge, Attitude and Practices Related to Hepatitis C Screening and Treatment in the Oral Direct Acting Antiviral Agents Era 2016, 06, | | 19 | Citations (PDF) |
| 135 | Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials | 1.2 | 2 | Citations (PDF) |
| 136 | About This Continuing Medical Education Activity | 3.8 | 1 | Citations (PDF) |
| 137 | Interaction Between Alcohol Consumption Patterns, Antiretroviral Therapy Type, and Liver Fibrosis in Persons Living with HIV | 2.1 | 29 | Citations (PDF) |
| 138 | Public health clinic‐based hepatitis C testing and linkage to care in baltimore | 1.2 | 57 | Citations (PDF) |
| 139 | 499 Ribavirin-Free Regimen With Velpatasvir and Sofosbuvir is Associated With High Efficiency and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From ASTRAL-2 and 3 Clinical Trials | 0.9 | 0 | Citations (PDF) |
| 140 | 751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin | 0.9 | 0 | Citations (PDF) |
| 141 | Sofosbuvir and Velpatasvir for Patients with HCV Infection | 19.4 | 21 | Citations (PDF) |
| 142 | Serum Fibrosis Markers for the Diagnosis of Liver Disease Among People With Chronic Hepatitis C in Chennai, India | 0.7 | 6 | Citations (PDF) |
| 143 | HCV‐HIV co‐infected patients: no longer a ‘special’ population? | 3.1 | 28 | Citations (PDF) |
| 144 | Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response | 0.9 | 207 | Citations (PDF) |
| 145 | Morbidity and Mortality Among Community-Based People Who Inject Drugs With a High Hepatitis C and Human Immunodeficiency Virus Burden in Chennai, India | 0.7 | 15 | Citations (PDF) |
| 146 | Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir: Table 1. | 3.8 | 13 | Citations (PDF) |
| 147 | Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies | 0.9 | 0 | Citations (PDF) |
| 148 | Senior Center-Based Hepatitis C Screening in Baltimore | 0.7 | 7 | Citations (PDF) |
| 149 | Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy: Table 1. | 3.8 | 57 | Citations (PDF) |
| 150 | Plasma and intracellular ribavirin concentrations are not significantly altered by abacavir in hepatitis C virus-infected patients | 2.1 | 5 | Citations (PDF) |
| 151 | Safety and efficacy of ledipasvir‐sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data | 9.5 | 57 | Citations (PDF) |
| 152 | Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection | 0.9 | 170 | Citations (PDF) |
| 153 | Burden of Liver Disease among Community-Based People Who Inject Drugs (PWID) in Chennai, India | 1.5 | 24 | Citations (PDF) |
| 154 | Development of sofosbuvir for the treatment of hepatitis C virus infection | 2.6 | 44 | Citations (PDF) |
| 155 | Statins Are Associated With Decreased Liver Disease Progression in HIV/HCV Co-Infected Adults | 0.7 | 1 | Citations (PDF) |
| 156 | Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons | 1.5 | 11 | Citations (PDF) |
| 157 | Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease | 0.9 | 752 | Citations (PDF) |
| 158 | Antiretroviral Effects on Host Lipoproteins Are Associated With Changes in Hepatitis C Virus (HCV) RNA Levels in Human Immunodeficiency Virus/HCV Coinfected Individuals | 0.7 | 0 | Citations (PDF) |
| 159 | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection | 19.4 | 796 | Citations (PDF) |
| 160 | Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes | 2.2 | 56 | Citations (PDF) |
| 161 | Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial | 6.0 | 292 | Citations (PDF) |
| 162 | Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1 | 19.4 | 398 | Citations (PDF) |
| 163 | Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1 | 19.4 | 451 | Citations (PDF) |
| 164 | 901d Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study | 0.9 | 2 | Citations (PDF) |
| 165 | 364 An Integrated Safety, Efficacy, and Virology Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin | 0.9 | 0 | Citations (PDF) |
| 166 | Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials | 9.5 | 86 | Citations (PDF) |
| 167 | Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1 | 15.8 | 298 | Citations (PDF) |
| 168 | Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection | 15.8 | 88 | Citations (PDF) |
| 169 | Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct‐acting antivirals has failed | 9.5 | 23 | Citations (PDF) |
| 170 | Extrahepatic Morbidity and Mortality of Chronic Hepatitis C | 0.9 | 335 | Citations (PDF) |
| 171 | Current and Evolving Treatments of Genotype 1 Hepatitis C Virus | 1.7 | 18 | Citations (PDF) |
| 172 | Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial | 45.2 | 265 | Citations (PDF) |
| 173 | Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: a cross-sectional study | 9.5 | 94 | Citations (PDF) |
| 174 | Concordance of sustained virological response 4, 12, and 24 weeks post‐treatment with sofosbuvir‐containing regimens for hepatitis C virus | 9.5 | 191 | Citations (PDF) |
| 175 | Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study | 10.4 | 105 | Citations (PDF) |
| 176 | Ledipasvir/Sofosbuvir Is Safe and Effective for the Treatment of Patients With Genotype 1 Chronic HCV Infection in Both HCV Mono-and HCV/HIV Co-Infected Patients | 0.7 | 1 | Citations (PDF) |
| 177 | Hepatitis C virus infection in HIV-infected patients | 1.4 | 17 | Citations (PDF) |
| 178 | 1223Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis | 0.7 | 0 | Citations (PDF) |
| 179 | 1291Sexually Transmitted Diseases Clinic Based Hepatitis C Testing and Linkage to Care | 0.7 | 1 | Citations (PDF) |
| 180 | Interferon-Containing and Interferon-Free HCV Therapy for HIV-Infected Patients | 2.0 | 8 | Citations (PDF) |
| 181 | Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: Prospective analysis of 435 liver biopsy pairs | 9.5 | 91 | Citations (PDF) |
| 182 | Overall safety profile of boceprevir plus peginterferon alfa‐2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials | 3.1 | 16 | Citations (PDF) |
| 183 | Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection | 15.8 | 237 | Citations (PDF) |
| 184 | Su1053 Virological Response in Treatment-Naïve Patients With Chronic HCV Genotype-1 Infection Receiving Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin Is Unaffected by Ribavirin Dose Reduction | 0.9 | 2 | Citations (PDF) |
| 185 | All-Oral Combination of Ledipasvir, Vedroprevir, Tegobuvir, and Ribavirin in Treatment-Naïve Patients With Genotype 1 HCV Infection | 9.5 | 44 | Citations (PDF) |
| 186 | Cost Analysis of Sofosbuvir/Ribavirin Versus Sofosbuvir/Simeprevir for Genotype 1 Hepatitis C Virus in Interferon-Ineligible/Intolerant Individuals | 9.5 | 104 | Citations (PDF) |
| 187 | Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients | 9.5 | 16 | Citations (PDF) |
| 188 | Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection | 19.4 | 1,274 | Citations (PDF) |
| 189 | Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1 | 19.4 | 267 | Citations (PDF) |
| 190 | 236 All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCVInfected Patients: The Phase 3 Ion-2 Study | 0.9 | 0 | Citations (PDF) |
| 191 | Virological response rates for telaprevir‐based hepatitis C triple therapy in patients with and without HIV coinfection | 1.8 | 28 | Citations (PDF) |
| 192 | Daclatasvir plus Sofosbuvir for HCV Infection | 19.4 | 61 | Citations (PDF) |
| 193 | Cost‐effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection | 2.6 | 63 | Citations (PDF) |
| 194 | Interferon γ–Induced Protein10 Kinetics in Treatment-Naive Versus Treatment-Experienced Patients Receiving Interferon-Free Therapy for Hepatitis C Virus Infection: Implications for the Innate Immune Response | 2.2 | 19 | Citations (PDF) |
| 195 | Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study | 45.2 | 773 | Citations (PDF) |
| 196 | Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin | 19.4 | 546 | Citations (PDF) |
| 197 | Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection | 19.4 | 1,100 | Citations (PDF) |
| 198 | 235 SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults With Hepatitis C Virus Genotype 1 | 0.9 | 0 | Citations (PDF) |
| 199 | Su1049 Faldaprevir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment-Naïve Patients With Chronic Hepatitis C Genotype-1 Infection: A Pooled Analysis of Two Randomized, Double-Blind Placebo-Controlled Phase III Trials (Startverso1&2) | 0.9 | 5 | Citations (PDF) |
| 200 | Su1060 Faldaprevir Plus Pegylated Interferon/Ribavirin Did Not Increase Anaemia Compared With Pegylated Interferon/Ribavirin in HCV Genotype-1, Treatment-Naïve Patients: Pooled Analysis of Phase III Studies | 0.9 | 0 | Citations (PDF) |
| 201 | 237 Successful Retreatment of HCV Genotype-1 Infected Patients Who Failed Prior Therapy With Peginterferon + Ribavirin Plus 1 or 2 Other Direct-Acting Antiviral Agents With Sofosbuvir | 0.9 | 0 | Citations (PDF) |
| 202 | Itx 5061 Quantitation in Human Plasma with Reverse Phase Liquid Chromatography and Mass Spectrometry Detection | 1.8 | 2 | Citations (PDF) |
| 203 | Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial | 9.5 | 177 | Citations (PDF) |
| 204 | Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial | 9.5 | 64 | Citations (PDF) |
| 205 | Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial | 9.5 | 103 | Citations (PDF) |
| 206 | Current Management of Hepatitis C Virus Infection in Patients With HIV Co-infection | 2.2 | 48 | Citations (PDF) |
| 207 | Effects of Ribavirin Dose Reduction vs Erythropoietin for Boceprevir-Related Anemia in Patients With Chronic Hepatitis C Virus Genotype 1 Infection—A Randomized Trial | 0.9 | 52 | Citations (PDF) |
| 208 | Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics | 2.7 | 29 | Citations (PDF) |
| 209 | HCV therapy in HIV‐infected patients | 3.1 | 31 | Citations (PDF) |
| 210 | Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial | 9.5 | 67 | Citations (PDF) |
| 211 | Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options | 19.4 | 1,012 | Citations (PDF) |
| 212 | Analysis of Site Performance in Academic-based and Community-based Centers in the IDEAL Study | 1.3 | 4 | Citations (PDF) |
| 213 | The new paradigm of hepatitis C therapy: integration of oral therapies into best practices | 1.2 | 78 | Citations (PDF) |
| 214 | Peginterferon-??-2a (40kD) and Ribavirin in Patients with Chronic Hepatitis C | 4.2 | 3 | Citations (PDF) |
| 215 | Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCV | 15.8 | 185 | Citations (PDF) |
| 216 | Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy | 4.0 | 4 | Citations (PDF) |
| 217 | Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C in HIV-Infected Persons | 3.8 | 27 | Citations (PDF) |
| 218 | Stability of Liver Fibrosis among HCV-Infected Injection Drug Users | 1.8 | 14 | Citations (PDF) |
| 219 | Peginterferon alfa-2a Plus Ribavirin for HIV-HCV Genotype 1 Coinfected Patients: A Randomized International Trial | 2.0 | 66 | Citations (PDF) |
| 220 | 594 Ribavirin Dose Modification in Treatment-NaïVE and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies | 0.9 | 3 | Citations (PDF) |
| 221 | Management of Patients Coinfected With HCV and HIV: A Close Look at the Role for Direct-Acting Antivirals | 0.9 | 80 | Citations (PDF) |
| 222 | Factors That Predict Response of Patients With Hepatitis C Virus Infection to Boceprevir | 0.9 | 180 | Citations (PDF) |
| 223 | Hepatitis C genotype 1 infection in HIV-Infected patients in the era of direct-acting antiviral therapy | 0.5 | 1 | Citations (PDF) |
| 224 | Hepatitis C virus‐human immunodeficiency virus coinfection | 3.1 | 20 | Citations (PDF) |
| 225 | Infections During Peginterferon (pegIFN)/Ribavirin (RBV) Therapy Are Associated With a Decline in Lymphocyte Count: Results of the IDEAL Study | 0.9 | 0 | Citations (PDF) |
| 226 | Adherence to Assigned Dosing Regimen and Sustained Virologic Response Among Hepatitis C Genotype 1 Treatment-NaïVE and PEG/Ribavirin Treatment-Failures Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin | 0.9 | 0 | Citations (PDF) |
| 227 | Rapid Fibrosis Progression Among HIV/Hepatitis C Virus (HCV) Coinfected Adults: Prospective Analysis of 446 Liver Biopsy Pairs | 0.9 | 0 | Citations (PDF) |
| 228 | Thyroid Stimulating Hormone (TSH) and Peginterferon Treatment Induced Hypothyroidism May Be Associated With Phosphodiesterase Polymorphisms in Patients With Chronic Hepatitis C | 0.9 | 0 | Citations (PDF) |
| 229 | Effect of Cigarette Smoking on Virologic Response in Patients Treated for Chronic Hepatitis C (CHC) in the IDEAL Study | 0.9 | 0 | Citations (PDF) |
| 230 | Four-Week Therapy With Peginterferon Alfa-2B/Ribavirin Effectively Predicts Sustained Virologic Response in Treatment-NaïVE and Previous-Treatment-Failure Patients With HCV-1 Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin | 0.9 | 1 | Citations (PDF) |
| 231 | Incidence and Risk Factors for Steatosis Progression in Adults Coinfected With HIV and Hepatitis C Virus | 0.9 | 54 | Citations (PDF) |
| 232 | Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection | 19.4 | 722 | Citations (PDF) |
| 233 | Boceprevir for Untreated Chronic HCV Genotype 1 Infection | 19.4 | 2,393 | Citations (PDF) |
| 234 | Anemia During Treatment With Peginterferon Alfa-2B/Ribavirin With or Without Boceprevir is Associated With Higher SVR Rates: Analysis of Previously Untreated and Previous-Treatment-Failure Patients | 0.9 | 4 | Citations (PDF) |
| 235 | IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy | 0.9 | 12 | Citations (PDF) |
| 236 | Gender Differences in Hepatitis C Virus (HCV) Treatment Outcomes With Peginterferon (pegIFN) Plus Ribavirin (RBV): An Analysis of the IDEAL Study | 0.9 | 0 | Citations (PDF) |
| 237 | Anemia Had No Effect on Efficacy Outcomes in Treatment-NaïVE Patients Who Received Telaprevir-Based Regimen in the Advance and Illuminate Phase 3 Studies | 0.9 | 7 | Citations (PDF) |
| 238 | Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection | 7.4 | 30 | Citations (PDF) |
| 239 | Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | 31.1 | 139 | Citations (PDF) |
| 240 | Racial differences in hepatitis C treatment eligibility | 9.5 | 50 | Citations (PDF) |
| 241 | Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African–American elite controllers/suppressors | 1.5 | 20 | Citations (PDF) |
| 242 | Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C) | 1.1 | 26 | Citations (PDF) |
| 243 | ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C | 31.3 | 436 | Citations (PDF) |
| 244 | Lessons From HIV Therapy Applied to Viral Hepatitis Therapy: Summary of a Workshop | 0.6 | 31 | Citations (PDF) |
| 245 | Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons | 1.5 | 10 | Citations (PDF) |
| 246 | S1850 The Natural History of Hepatic Steatosis Among HIV/Hepatitis C Co-Infected Adults With Paired Liver Biopsy | 0.9 | 0 | Citations (PDF) |
| 247 | T2005 Dynamics of Apoptotic Activity in Patients With Chronic Hepatitis C Treated With Albinterferon Alfa-2B or Peginterferon Alfa-2a | 0.9 | 0 | Citations (PDF) |
| 248 | MELD Score Is an Important Predictor of Pretransplantation Mortality in HIV-Infected Liver Transplant Candidates | 0.9 | 81 | Citations (PDF) |
| 249 | Hepatitis C Virus Treatment-Related Anemia Is Associated With Higher Sustained Virologic Response Rate | 0.9 | 103 | Citations (PDF) |
| 250 | Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus | 0.9 | 643 | Citations (PDF) |
| 251 | Assessment of Liver Fibrosis by Transient Elastography in Persons with Hepatitis C Virus Infection or HIV–Hepatitis C Virus Coinfection | 3.8 | 141 | Citations (PDF) |
| 252 | Hepatic profile analyses of tipranavir in Phase II and III clinical trials | 1.7 | 17 | Citations (PDF) |
| 253 | Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | 31.3 | 3,482 | Citations (PDF) |
| 254 | Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection | 19.4 | 1,179 | Citations (PDF) |
| 255 | Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection | 19.4 | 1,043 | Citations (PDF) |
| 256 | 10 Decline in Hemoglobin Is Associated with Sustained Virologic Response (SVR) Among HCV Genotype 1-Infected Persons Treated with Peginterferon (PEG)/Ribavirin (RBV): Analysis from the Ideal Study | 0.9 | 1 | Citations (PDF) |
| 257 | Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitutionAids, 2009, 23, 2397-2404 | 1.5 | 60 | Citations (PDF) |
| 258 | Specific targeted antiviral therapy for hepatitis C | 2.2 | 19 | Citations (PDF) |
| 259 | Viral hepatitis and HIV coinfection | 7.4 | 270 | Citations (PDF) |
| 260 | Detection of Liver Disease in Injection Drug Users | 1.0 | 3 | Citations (PDF) |
| 261 | Efficacy and Safety of Peginterferon Alfa-2a/Ribavirin in Methadone Maintenance Patients: Randomized Comparison of Direct Observed Therapy and Self-Administration | 0.6 | 42 | Citations (PDF) |
| 262 | Management of Hepatic Complications in HIV‐Infected Persons | 2.2 | 74 | Citations (PDF) |
| 263 | Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events | 1.5 | 50 | Citations (PDF) |
| 264 | Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adultsAids, 2007, 21, 2209-2216 | 1.5 | 174 | Citations (PDF) |
| 265 | Needlestick Injuries among Surgeons in Training | 19.4 | 283 | Citations (PDF) |
| 266 | Therapeutic issues in HIV/HCV-coinfected patients | 1.2 | 72 | Citations (PDF) |
| 267 | Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection | 2.2 | 21 | Citations (PDF) |
| 268 | Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinicAids, 2006, 20, 2361-2369 | 1.5 | 123 | Citations (PDF) |
| 269 | Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons | 1.2 | 116 | Citations (PDF) |
| 270 | Global transcriptional effects of PEG-IFN-α and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C | 1.9 | 0 | Citations (PDF) |
| 271 | Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection | 9.5 | 4,672 | Citations (PDF) |
| 272 | Perspectives on HIV/hepatitis C virus co-infection, illicit drug use and mental illness | 1.5 | 18 | Citations (PDF) |
| 273 | Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus | 1.5 | 162 | Citations (PDF) |
| 274 | Peginterferon Alfa-2a Does Not Alter the Pharmacokinetics of Methadone in Patients with Chronic Hepatitis C Undergoing Methadone Maintenance Therapy* | 2.7 | 34 | Citations (PDF) |
| 275 | The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection | 9.5 | 114 | Citations (PDF) |
| 276 | Treatment of Chronic Hepatitis B in HIV-Infected Persons: Thinking Outside the Black Box | 3.8 | 25 | Citations (PDF) |
| 277 | Epidemiology and Natural History of Hepatitis C Virus Infection in Injection Drug Users: Implications for Treatment | 3.8 | 43 | Citations (PDF) |
| 278 | Therapy Insight: management of hepatitis C in patients coinfected with HIV | 4.0 | 1 | Citations (PDF) |
| 279 | Pilot Study of Low‐Dose Interleukin‐2, Pegylated Interferon–α2b, and Ribavirin for the Treatment of Hepatitis C Virus Infection in Patients with HIV Infection | 2.2 | 13 | Citations (PDF) |
| 280 | Epoetin Alfa Once Weekly Improves Anemia in HIV/Hepatitis C Virus-Coinfected Patients Treated With Interferon/Ribavirin: A Randomized Controlled Trial | 1.1 | 35 | Citations (PDF) |
| 281 | A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug usersAids, 2005, 19, S179-S189 | 1.5 | 54 | Citations (PDF) |
| 282 | Management of the Hematologic Complications of Hepatitis C Therapy | 1.6 | 43 | Citations (PDF) |
| 283 | Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: The SHASTA index | 7.4 | 202 | Citations (PDF) |
| 284 | Liver enzyme values in injection drug users with chronic hepatitis C | 1.9 | 5 | Citations (PDF) |
| 285 | Hepatitis C Virus in the Setting of HIV or Hepatitis B Virus Coinfection | 2.0 | 46 | Citations (PDF) |
| 286 | Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors | 3.8 | 191 | Citations (PDF) |
| 287 | Changes in haemoglobin during interferon alpha‐2b plus ribavirin combination therapy for chronic hepatitis C virus infection | 1.2 | 142 | Citations (PDF) |
| 288 | Hepatitis C virus infection in HIV-infected patients | 2.4 | 11 | Citations (PDF) |
| 289 | Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy | 9.5 | 136 | Citations (PDF) |
| 290 | HAART and the HCV-infected liver: friend or foe? | 7.4 | 0 | Citations (PDF) |
| 291 | Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study1 1The other PROACTIVE Study Group investigators included the following: Vijayan Balan, M.D., Mayo Clinic Scottsdale, Scottsdale, Arizona; Norbert Bräu, M.D., Bronx VA Medical Center, Bronx, New York; Robert Brown, M.D., M.P.H., NY Presbyterian Medical Center, New York, New York; William Carey, M.D., Cleveland Clinic Foundation, Cleveland, Ohio; Andrea Duchini, M.D., Baylor College of Medi | 0.9 | 547 | Citations (PDF) |
| 292 | HAART and the HCV-infected liver: friend or foe? | 7.4 | 4 | Citations (PDF) |
| 293 | Daily Versus Thrice-Weekly Interferon Alfa-2b Plus Ribavirin for the Treatment of Chronic Hepatitis C in HIV-Infected Persons: A Multicenter Randomized Controlled Trial | 1.1 | 21 | Citations (PDF) |
| 294 | Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavirAids, 2004, 18, 2277-2284 | 1.5 | 145 | Citations (PDF) |
| 295 | Antiretroviral-associated liver injury | 1.6 | 56 | Citations (PDF) |
| 296 | Hepatitis C in the HIV-infected patient | 1.6 | 51 | Citations (PDF) |
| 297 | PEG-interfeoon α-2b + ribavirin for treatment of patients with chronic hepatitis C who have previously failed to achieve a sustained virologic response following interferon alfa or interferon a-2b + ribavirin therapy | 0.9 | 4 | Citations (PDF) |
| 298 | Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus–infected patients receiving ribavirin plus interferon alfa | 0.6 | 1 | Citations (PDF) |
| 299 | Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa | 0.6 | 208 | Citations (PDF) |
| 300 | Hepatotoxicity Associated with Antiretroviral Therapy Containing HIV-1 Protease Inhibitors | 2.0 | 80 | Citations (PDF) |
| 301 | The Effect of HAART and HCV Infection on the Development of Hyperglycemia Among HIV-Infected Persons | 1.1 | 88 | Citations (PDF) |
| 302 | Hepatitis C in the HIV-Infected Person | 7.3 | 349 | Citations (PDF) |
| 303 | Needlestick Transmission of Hepatitis C | 15.8 | 106 | Citations (PDF) |
| 304 | Hepatitis C and Progression of HIV Disease | 15.8 | 397 | Citations (PDF) |
| 305 | Treatment of chronic hepatitis C: A systematic review | 9.5 | 87 | Citations (PDF) |
| 306 | Hepatitis C virus infection in HIV-infected patients | 1.0 | 1 | Citations (PDF) |
| 307 | Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections | 9.5 | 445 | Citations (PDF) |
| 308 | Once-weekly recombinant human erythropoetin (Epoetin alfa) facilitates optimal ribavirin (RBV) dosing in hepatitis C virus (HCV)-infected patients receiving interferon-α-2b (IFN)/RBV combination therapy | 0.9 | 6 | Citations (PDF) |
| 309 | Association of Hepatitis C and Diabetes Mellitus | 7.3 | 0 | Citations (PDF) |
| 310 | Hepatitis C virus infection in HIV-infected patients | 1.4 | 33 | Citations (PDF) |
| 311 | Interferon and Ribavirin vs Interferon Alone in the Re-treatment of Chronic Hepatitis C Previously Nonresponsive to Interferon | 15.8 | 150 | Citations (PDF) |
| 312 | Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States | 9.5 | 0 | Citations (PDF) |
| 313 | Prevalence of Type 2 Diabetes Mellitus among Persons with Hepatitis C Virus Infection in the United States | 7.3 | 623 | Citations (PDF) |
| 314 | Hepatitis C Virus Infection as an Opportunistic Disease in Persons Infected with Human Immunodeficiency Virus | 3.8 | 248 | Citations (PDF) |
| 315 | Hepatotoxicity Associated With Antiretroviral Therapy in Adults Infected With Human Immunodeficiency Virus and the Role of Hepatitis C or B Virus Infection | 15.8 | 842 | Citations (PDF) |
| 316 | The Effect of Acute Infectious Illnesses on Plasma Human Immunodeficiency Virus (HIV) Type 1 Load and the Expression of Serologic Markers of Immune Activation among HIV‐Infected Adults | 2.2 | 107 | Citations (PDF) |
| 317 | Combination Therapy With Telaprevir for Chronic Hepatitis C Virus Genotype 1 Infection in Patients With HIV | 7.3 | 193 | Citations (PDF) |
| 318 | No Evidence of Reactivation of Hepatitis B Virus Among Patients Treated With Ledipasvir-Sofosbuvir for Hepatitis C Virus Infection | 3.8 | 61 | Citations (PDF) |
| 319 | Title is missing! 0 | | 1 | Citations (PDF) |
| 320 | MINMON-J: a hybrid implementation pilot study evaluating a low-barrier hepatitis C treatment model in a jail setting | 1.2 | 2 | Citations (PDF) |
| 321 | Impact of HCV cure on systemic inflammation and bone density, quality, and turnover | 3.3 | 2 | Citations (PDF) |
| 322 | Utilizing Telemedicine to Engage Rural Patients With Substance Use Disorders in Low Barrier Hepatitis C Treatment | 1.2 | 1 | Citations (PDF) |
| 323 | Metformin on the Presence of COVID-19 Symptoms 6 Months After Infection: The ACTIV-6 Randomized Clinical Trial | 3.8 | 1 | Citations (PDF) |
| 324 | Prevalence of Hepatitis B Coinfection in People With HIV by Birth-Year Cohort | 0.7 | 0 | Citations (PDF) |
